Literature DB >> 8782458

Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes.

N Zavazava1, M Krönke.   

Abstract

Soluble HLA class I molecules (sHLAs) have been identified in the serum of patients with inflammatory diseases, allografts and autoimmune diseases and in serum of healthy individuals. The biological significance of these molecules, particularly after allogeneic organ transplantation, has been enigmatic. Here we show that primary alloreactive CD8+ T cells interact with sHLA and undergo apoptosis in the absence of a second signal. Ligation of CD28 rescued T cells from death, implying that sHLAs induce apoptosis through selective stimulation of the T-cell receptor. CD95-L was upregulated after cytotoxic T lymphocytes were incubated with sHLAs, and cell death was blocked by a neutralizing anti-CD95-L antibody, suggesting that sHLAs induce endogenous mutual killing of activated T cells. These results provide a molecular basis for the capacity of sHLAs to downregulate T-cell responses, which may be especially relevant to organ transplantation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8782458     DOI: 10.1038/nm0996-1005

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  32 in total

1.  Inhibition of Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocyte (CTL) activity by soluble HLA class I in vitro.

Authors:  B Gansuvd; M Hagihara; B Munkhbat; N Kanai; N Morita; N Munkhtuvshin; J Chargui; S Kato; T Hotta; K Tsuji
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

2.  Inhibition of allorecognition by a human class II MHC-derived peptide through the induction of apoptosis.

Authors:  B Murphy; C C Magee; S I Alexander; A M Waaga; H W Snoeck; J P Vella; C B Carpenter; M H Sayegh
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

3.  Induction of T cell anergy by liposomes with incorporated major histocompatibility complex (MHC) II/peptide complexes.

Authors:  A J van Rensen; L S Taams; M C Grosfeld-Stulemeyer; W van Eden; D J Crommelin; M H Wauben
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

Review 4.  Interplay between T helper type 1 and type 2 cytokines and soluble major histocompatibility complex molecules: a paradigm in pregnancy.

Authors:  Irene Athanassakis; S Vassiliadis
Journal:  Immunology       Date:  2002-11       Impact factor: 7.397

5.  Mining the plasma immunopeptidome for cancer peptides as biomarkers and beyond.

Authors:  Heather D Hickman; Jonathan W Yewdell
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

6.  Expression and functional role of HLA-G in immune cells from patients with systemic lupus erythematosus.

Authors:  Adriana Elizabeth Monsiváis-Urenda; Lourdes Baranda; Crisol Alvarez-Quiroga; Carlos Abud-Mendoza; Roberto González-Amaro
Journal:  J Clin Immunol       Date:  2010-12-29       Impact factor: 8.317

Review 7.  Soluble HLA: patterns of expression in normal subjects, autoimmune diseases, and transplant recipients.

Authors:  Irena Adamashvili; Roger E Kelley; Thomas Pressly; John C McDonald
Journal:  Rheumatol Int       Date:  2005-06-29       Impact factor: 2.631

Review 8.  Soluble HLA revisited.

Authors:  William B Tabayoyong; Nicholas Zavazava
Journal:  Leuk Res       Date:  2006-07-24       Impact factor: 3.156

9.  Soluble plasma HLA peptidome as a potential source for cancer biomarkers.

Authors:  Michal Bassani-Sternberg; Eilon Barnea; Ilan Beer; Irit Avivi; Tami Katz; Arie Admon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

Review 10.  Soluble HLA-G: Are they clinically relevant?

Authors:  Vito Pistoia; Fabio Morandi; Xinhui Wang; Soldano Ferrone
Journal:  Semin Cancer Biol       Date:  2007-07-31       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.